Core Viewpoint - The report by Zhiyan Consulting highlights the growth trends in China's chemical pharmaceutical industry, projecting a production increase in raw chemical drugs by 3.4% year-on-year in April 2025, with a cumulative growth of 3.9% from January to April 2025 [1] Industry Summary - In April 2025, China's production of raw chemical drugs reached 332,000 tons, marking a year-on-year increase of 3.4% [1] - The cumulative production of raw chemical drugs from January to April 2025 totaled 1,257,000 tons, reflecting a cumulative growth of 3.9% [1] - The report provides insights into the supply and demand dynamics of the chemical pharmaceutical industry in China from 2025 to 2031 [1] Company Summary - Listed companies in the report include Heng Rui Medicine, East China Pharmaceutical, Lijun Group, Baiyunshan, North China Pharmaceutical, Haizheng Pharmaceutical, Fosun Pharmaceutical, Kelun Pharmaceutical, Enhua Pharmaceutical, and Xianju Pharmaceutical [1] - Zhiyan Consulting is recognized as a leading industry consulting firm in China, specializing in in-depth industry research and providing comprehensive consulting services for investment decisions [1]

Core Viewpoint - Xianju Pharmaceutical stated that estradiol tablets are indicated for diseases related to estrogen deficiency and can also prevent osteoporosis [2] Group 1: Product Information - Estradiol tablets are used for conditions caused by estrogen deficiency [2] - The product can help in the prevention of osteoporosis [2] - Export of the formulation requires obtaining relevant product certification from foreign markets [2] Group 2: Usage Guidelines - Specific usage and dosage of prescription drugs should follow the advice of a physician [2]

Core Viewpoint - Xianju Pharmaceutical experienced a slight decline in stock price and notable trading activity, indicating potential investor concerns and market dynamics [1][2]. Financing Summary - On October 16, Xianju Pharmaceutical had a financing buy-in amount of 13.11 million yuan, with a net financing outflow of 2.94 million yuan, reflecting a high financing balance of 567 million yuan, which constitutes 5.81% of its market capitalization [1]. - The financing balance is above the 80th percentile of the past year, indicating a high level of investor engagement [1]. - The company also reported a securities lending situation with a total of 15.31 million shares available for lending, with a balance of 1.51 million yuan, also above the 80th percentile of the past year [1]. Business Performance - For the first half of 2025, Xianju Pharmaceutical reported a revenue of 1.869 billion yuan, a year-on-year decrease of 12.56%, and a net profit attributable to shareholders of 308 million yuan, down 9.26% year-on-year [2]. - The company's main revenue sources include corticosteroids (63.39%), gynecological and contraceptive drugs (20.69%), other medications (9.21%), and anesthetics and muscle relaxants (6.71%) [1]. Shareholder Information - As of September 30, the number of shareholders for Xianju Pharmaceutical stood at 50,000, with no change from the previous period [2]. - The cumulative cash dividends paid by the company since its A-share listing amount to 2.031 billion yuan, with 989 million yuan distributed over the last three years [3]. - Notably, the Southern CSI 1000 ETF is among the top ten circulating shareholders, increasing its holdings by 1.4094 million shares [3].

Group 1 - The company Xianju Pharmaceutical announced a cash dividend distribution plan for the first half of 2025, proposing a payment of 1.00 RMB per 10 shares to all shareholders [1] - The total number of shares used as the basis for the dividend distribution is 989,204,866 shares [1] - The record date for the dividend is set for October 21, 2025, and the ex-dividend date is October 22, 2025 [1]

3、本次实施的利润分配方案与公司 2025 年第二次临时股东大会审议通过 的分配方案一致。 4、本次实施的利润分配方案距公司 2025 年第二次临时股东大会审议通过 的时间未超过两个月。 二、本次权益分派方案 股票代码：002332 股票简称：仙琚制药 公告编号：2025-044 浙江仙琚制药股份有限公司 2025 年半年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"或"本公司"）2025 年半 年度权益分派方案已获 2025 年 9 月 19 日召开的公司 2025 年第二次临时股东大 会审议通过，现将权益分派事宜公告如下： 一、 股东大会审议通过权益分派方案情况 1、2025 年 9 月 19 日，公司 2025 年第二次临时股东大会审议通过《关于 2025 年半年度利润分配的预案》：以 2025 年 6 月 30 日的总股本 989,204,866 股 为基数，向全体股东每 10 股派发现金红利人民币 1.00 元（含税）。 2、公司 2025 年半年度利润分配方案以固定总额的方式分配，分配 ...

Core Viewpoint - Zhejiang Xianju Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the consistency evaluation of the quality and efficacy of its Acetate Dexamethasone Tablets, which enhances the company's market competitiveness [1][2]. Group 1: Drug Information - The company has successfully passed the consistency evaluation for the 0.5mg specification of Acetate Dexamethasone Tablets, with the drug approval number being Guoyao Zhunzi H20258221 [2]. - The 0.75mg specification of Acetate Dexamethasone Tablets was previously approved in August 2025 [2]. - Acetate Dexamethasone Tablets are corticosteroids primarily used for allergic and autoimmune inflammatory diseases, including connective tissue diseases, severe bronchial asthma, dermatitis, ulcerative colitis, acute leukemia, and malignant lymphoma [1]. Group 2: Regulatory and Approval Process - The approval was based on the Drug Administration Law of the People's Republic of China and relevant government opinions on the reform of drug and medical device review and approval systems [1]. - The product adheres to the national drug registration standards YBH26782025 set by the National Medical Products Administration [2]. Group 3: Company Impact - The approval of the 0.5mg specification is expected to strengthen and enhance the product's market competitiveness and provide valuable experience for future drug consistency evaluations [2].

Core Points - The company, Xianju Pharmaceutical, has received approval from the National Medical Products Administration for a supplemental application regarding Dexamethasone Acetate Tablets [2] - The newly approved specification for Dexamethasone Acetate Tablets has passed the consistency evaluation of quality and efficacy for generic drugs [2] Company Summary - Xianju Pharmaceutical is now authorized to market a new specification of Dexamethasone Acetate Tablets, which enhances its product portfolio [2] - The approval signifies the company's commitment to maintaining high standards in drug quality and efficacy [2]

Core Viewpoint - Xianju Pharmaceutical (002332.SZ) has received approval from the National Medical Products Administration for a supplemental application regarding Acetate Dexamethasone Tablets, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1: Product Approval - The company has obtained a notification for the approval of Acetate Dexamethasone Tablets, indicating regulatory compliance and potential market expansion [1] - The new specification of Acetate Dexamethasone Tablets enhances the product portfolio of the company [1] Group 2: Product Indications - Acetate Dexamethasone Tablets are classified as corticosteroids and are primarily used for allergic and autoimmune inflammatory diseases [1] - Indications include connective tissue diseases, severe bronchial asthma, dermatitis, ulcerative colitis, acute leukemia, and malignant lymphoma [1]

证券代码：002332 证券简称：仙琚制药 公告编号：2025-043 浙江仙琚制药股份有限公司 关于醋酸地塞米松片新增规格通过一致性评价的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"）于近日收到国家药品 监督管理局核准签发的关于醋酸地塞米松片的《药品补充申请批准通知书》 （通知书编号：2025B04681），公司醋酸地塞米松片新增规格通过仿制药质 量和疗效一致性评价。现将相关情况公告如下： 1 药品名称 剂型 规格 药品注册 标准编号 注册分类 药品生产 企业 醋酸地塞米松片 片剂 0.5mg YBH26782025 化学药品 浙江仙琚制药股 份有限公司 一、药品基本信息 0.5mg，药品批准文号为：国药准字H20258221，目前产品执行标准为国家药 品监督管理局药品注册标准YBH26782025。 三、对公司的影响及风险提示 公司醋酸地塞米松片0.5mg规格通过仿制药质量和疗效一致性评价，有利 于巩固和提升产品市场竞争力，为公司后续药品一致性评价工作积累经验。 申请内容：申报仿制药质量和疗效一致性评价。 ...

Group 1 - The core viewpoint of the article highlights the growth in China's chemical pharmaceutical raw material production, with a reported output of 329,000 tons in May 2025, reflecting a year-on-year increase of 3.8% [1] - Cumulative production of chemical pharmaceutical raw materials from January to May 2025 reached 1,585,000 tons, showing a cumulative growth of 5% [1] - The article references a report by Zhiyan Consulting, which provides insights into the market supply and demand trends in the Chinese chemical pharmaceutical industry from 2025 to 2031 [1] Group 2 - The listed companies in the article include Heng Rui Medicine, East China Medicine, Li Zhu Group, Baiyunshan, North China Pharmaceutical, Hai Zheng Pharmaceutical, Fosun Pharmaceutical, Ke Lun Pharmaceutical, En Hua Pharmaceutical, and Xian Ju Pharmaceutical [1] - Zhiyan Consulting is described as a leading industry consulting firm in China, specializing in in-depth industry research reports, business plans, feasibility studies, and customized services [1] - The article emphasizes Zhiyan Consulting's commitment to providing comprehensive industry solutions to empower investment decisions through professional insights and market acumen [1]